Zkusit zdarma
Ovid Therapeutics Inc.

Ovid Therapeutics Inc.

OVID
Cena:
$ 2.47
+0.03 (1.23%)
Valuace
70
Růst
0
Zdraví
74
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

7:00 12-05-2026

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) d...

AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials

AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials

8:36 27-04-2026

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID He...

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

18:41 14-04-2026

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transc...

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

8:00 08-04-2026

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceuti...

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Brokerages

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Brokerages

2:50 26-03-2026

Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have received an average rating of "Buy...

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

7:45 20-03-2026

Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal o...

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Analysts

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Analysts

2:04 10-01-2026

Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have been given a consensus rating of "...

Assenagon Asset Management S.A. Purchases 488,956 Shares of Ovid Therapeutics $OVID

Assenagon Asset Management S.A. Purchases 488,956 Shares of Ovid Therapeutics $OVID

3:21 25-12-2025

Assenagon Asset Management S.A. lifted its position in shares of Ovid Therapeutics (NASDAQ: OVID) by...

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

8:00 18-12-2025

OV350 showed a good safety profile, supporting the advancement of the Company's KCC2 portfolio, incl...

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

7:00 02-12-2025

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutic...

Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates

Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates

9:11 12-11-2025

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensu...

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

7:00 12-11-2025

Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to tr...

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

11:01 04-11-2025

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a like...

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data

11:31 10-10-2025

Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of i...

Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know

Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know

13:01 06-10-2025

Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let'...

Ovid Therapeutics Inc. - Special Call

Ovid Therapeutics Inc. - Special Call

12:52 03-10-2025

Ovid Therapeutics Inc. - Special Call Company Participants Victoria Fort - Senior Vice President of ...

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

7:05 03-10-2025

Initial closing of approximately $81 million expected to fund current operating plan and clinical pi...

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

7:00 03-10-2025

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutic...

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

10:26 13-08-2025

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.06 per share versus the Zacks Consensu...

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

8:00 13-08-2025

Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for ...

close

OVID THERAPEUTICS REPORTS PHASE 1 RESULTS FOR THE FIRST-EVER DIRECT ACTIVATOR OF POTASSIUM-CHLORIDE COTRANSPORTER 2 (KCC2), OV350 INTRAVENOUS (IV)

18-12-2025
OV350 SHOWED A GOOD SAFETY PROFILE, SUPPORTING THE ADVANCEMENT OF THE COMPANY'S KCC2 PORTFOLIO, INCL...
Více zde

OVID THERAPEUTICS APPOINTS DR. PETRA KAUFMANN AS CHIEF MEDICAL OFFICER

02-12-2025
NEW YORK, DEC. 02, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTIC...
Více zde

OVID THERAPEUTICS ANNOUNCES PLANNED LEADERSHIP SUCCESSION AND REPORTS BUSINESS UPDATES AND THIRD QUARTER 2025 FINANCIAL RESULTS

12-11-2025
MEG ALEXANDER APPOINTED CHIEF EXECUTIVE OFFICER EFFECTIVE JANUARY 1, 2026; DR. JEREMY M. LEVIN TO TR...
Více zde

OVID THERAPEUTICS ANNOUNCES PRICING OF PRIVATE PLACEMENT TOTALING UP TO $175 MILLION IN GROSS PROCEEDS

03-10-2025
INITIAL CLOSING OF APPROXIMATELY $81 MILLION EXPECTED TO FUND CURRENT OPERATING PLAN AND CLINICAL PI...
Více zde

OVID ANNOUNCES POSITIVE TOPLINE RESULTS FOR THE NEXT-GENERATION GABA-AMINOTRANSFERASE INHIBITOR, OV329, THAT DEMONSTRATE STRONG INHIBITORY ACTIVITY AND A POTENTIAL BEST-IN-CATEGORY SAFETY PROFILE

03-10-2025
NEW YORK, OCT. 03, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTIC...
Více zde

OVID THERAPEUTICS REPORTS BUSINESS UPDATES AND SECOND QUARTER 2025 FINANCIAL RESULTS

13-08-2025
TOPLINE RESULTS FROM THE OV329 PHASE 1 SAFETY, TOLERABILITY AND BIOMARKER STUDY REMAIN ON TRACK FOR ...
Více zde

OVID THERAPEUTICS TO PARTICIPATE IN THE BTIG VIRTUAL BIOTECH CONFERENCE

23-07-2025
NEW YORK, JULY 23, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTIC...
Více zde

OVID THERAPEUTICS ENTERS AGREEMENT WITH IMMEDICA PHARMA AB FOR SALE OF FUTURE GANAXOLONE ROYALTIES

25-06-2025
NON-DILUTIVE FUNDING EXTENDS OVID'S OPERATIONAL RUNWAY; IMMEDICA ASSUMES CERTAIN GANAXOLONE IP COSTS...
Více zde

OVID THERAPEUTICS REPORTS BUSINESS UPDATES AND FIRST QUARTER 2025 FINANCIAL RESULTS

13-05-2025
TOPLINE PHARMACODYNAMIC BIOMARKER, SAFETY AND TOLERABILITY RESULTS FROM A PHASE 1 STUDY OF OV329 ARE...
Více zde

OVID THERAPEUTICS REPORTS BUSINESS UPDATES AND FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

11-03-2025
STELIOS PAPADOPOLOUS, PH.D., A PIONEERING LEADER IN BIOTECH, APPOINTED TO BOARD OF DIRECTORS; TWO IN...
Více zde

OVID THERAPEUTICS APPOINTS PIONEERING INDUSTRY LEADER DR. STELIOS PAPADOPOULOS TO BOARD OF DIRECTORS

03-03-2025
NEW YORK, MARCH 03, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTI...
Více zde

OVID THERAPEUTICS TO PRESENT AT THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE

27-02-2025
NEW YORK, FEB. 27, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTIC...
Více zde

OVID THERAPEUTICS TO PRESENT AT THE OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE

05-02-2025
NEW YORK, FEB. 05, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTIC...
Více zde

MEG ALEXANDER TAKES ON EXPANDED ROLE AS PRESIDENT AND COO AT OVID THERAPEUTICS, STRENGTHENING LEADERSHIP FOR FUTURE GROWTH

11-09-2024
NEW YORK, SEPT. 11, 2024 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTI...
Více zde

SHAREHOLDERS IN OVID THERAPEUTICS INC INVITED TO PARTICIPATE IN FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM

19-08-2024
LOS ANGELES, CA / ACCESSWIRE / AUGUST 19, 2024 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS ...
Více zde

OVID THERAPEUTICS INC INVESTORS ENCOURAGED TO JOIN FRAUD INVESTIGATION WITH SCHALL LAW FIRM

18-08-2024
LOS ANGELES, CA / ACCESSWIRE / AUGUST 18, 2024 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS ...
Více zde

OVID THERAPEUTICS INC SHAREHOLDERS ELIGIBLE TO PARTICIPATE IN FRAUD INVESTIGATION WITH SCHALL LAW FIRM

17-08-2024
LOS ANGELES, CA / ACCESSWIRE / AUGUST 17, 2024 / THE SCHALL LAW FIRM , A NATIONAL SHAREHOLDER RIGHTS...
Více zde

OVID THERAPEUTICS INC INVESTORS INVITED TO JOIN IN FRAUD INVESTIGATION WITH SCHALL LAW FIRM

16-08-2024
LOS ANGELES, CA / ACCESSWIRE / AUGUST 16, 2024 / THE SCHALL LAW FIRM , A NATIONAL SHAREHOLDER RIGHTS...
Více zde

OVID THERAPEUTICS INC SHAREHOLDERS ENCOURAGED TO JOIN FRAUD INVESTIGATION WITH SCHALL LAW FIRM

15-08-2024
LOS ANGELES, CA / ACCESSWIRE / AUGUST 15, 2024 / THE SCHALL LAW FIRM , A NATIONAL SHAREHOLDER RIGHTS...
Více zde

OVID THERAPEUTICS INC SHAREHOLDERS INVITED TO JOIN FRAUD INVESTIGATION WITH SCHALL LAW FIRM

14-08-2024
THE SCHALL LAW FIRM , A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGAT...
Více zde

OVID THERAPEUTICS INC INVESTORS WELCOME TO PARTICIPATE IN FRAUD INVESTIGATION WITH SCHALL LAW FIRM

14-08-2024
LOS ANGELES, CA / ACCESSWIRE / AUGUST 14, 2024 / THE SCHALL LAW FIRM , A NATIONAL SHAREHOLDER RIGHTS...
Více zde

OVID THERAPEUTICS REPORTS BUSINESS UPDATES AND SECOND QUARTER 2024 FINANCIAL RESULTS

13-08-2024
NEW YORK, AUG. 13, 2024 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTIC...
Více zde

OVID THERAPEUTICS INC INVESTORS INVITED TO JOIN FRAUD INVESTIGATION WITH SCHALL LAW FIRM

12-08-2024
LOS ANGELES, CA / ACCESSWIRE / AUGUST 12, 2024 / THE SCHALL LAW FIRM , A NATIONAL SHAREHOLDER RIGHTS...
Více zde

INVESTORS OF OVID THERAPEUTICS INC CAN PARTICIPATE IN FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM

09-08-2024
LOS ANGELES, CA / ACCESSWIRE / AUGUST 9, 2024 / THE SCHALL LAW FIRM , A NATIONAL SHAREHOLDER RIGHTS ...
Více zde

INVESTORS OF OVID THERAPEUTICS INC ELIGIBLE TO JOIN FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM

08-08-2024
LOS ANGELES, CA / ACCESSWIRE / AUGUST 8, 2024 / THE SCHALL LAW FIRM , A NATIONAL SHAREHOLDER RIGHTS ...
Více zde

INVESTORS OF OVID THERAPEUTICS INC CAN JOIN FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM

07-08-2024
THE SCHALL LAW FIRM , A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGAT...
Více zde

OVID THERAPEUTICS INC INVESTORS CAN PARTICIPATE IN FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM

06-08-2024
LOS ANGELES, CA / ACCESSWIRE / AUGUST 6, 2024 / THE SCHALL LAW FIRM , A NATIONAL SHAREHOLDER RIGHTS ...
Více zde

SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF OVID THERAPEUTICS INC. - OVID

03-08-2024
NEW YORK, AUG. 03, 2024 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...
Více zde

OVID INVESTORS HAVE OPPORTUNITY TO JOIN OVID THERAPEUTICS INC. FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM

02-08-2024
LOS ANGELES , AUG. 2, 2024 /PRNEWSWIRE/ -- THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGA...
Více zde

OVID INVESTORS HAVE OPPORTUNITY TO JOIN OVID THERAPEUTICS INC. FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM

01-08-2024
LOS ANGELES--(BUSINESS WIRE)--OVID INVESTORS HAVE OPPORTUNITY TO JOIN OVID THERAPEUTICS INC. FRAUD I...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2025-12-18 00:00:008-KStáhnout
2025-12-11 00:00:008-KStáhnout
2025-11-12 00:00:008-KStáhnout
2025-11-12 00:00:0010-QStáhnout
2025-10-03 01:00:008-KStáhnout
2025-10-03 00:00:008-KStáhnout
2025-09-16 01:00:008-KStáhnout
2025-09-16 00:00:008-KStáhnout
2025-08-13 01:00:008-KStáhnout
2025-08-13 01:00:0010-QStáhnout
2025-08-13 00:00:008-KStáhnout
2025-08-13 00:00:0010-QStáhnout
2025-07-10 01:00:008-KStáhnout
2025-07-10 00:00:008-KStáhnout
2025-06-25 01:00:008-KStáhnout
2025-06-25 00:00:008-KStáhnout
2025-05-13 01:00:008-KStáhnout
2025-05-13 01:00:0010-QStáhnout
2025-05-13 00:00:008-KStáhnout
2025-05-13 00:00:0010-QStáhnout
2025-05-02 01:00:008-KStáhnout
2025-05-02 00:00:008-KStáhnout
2025-03-11 00:00:008-KStáhnout
2025-03-11 00:00:0010-KStáhnout
2025-03-10 23:00:008-KStáhnout
2025-03-10 23:00:0010-KStáhnout
2025-03-05 00:00:008-KStáhnout
2025-03-04 23:00:008-KStáhnout
2025-02-13 00:00:008-KStáhnout
2025-02-12 23:00:008-KStáhnout
2024-11-12 00:00:008-KStáhnout
2024-11-12 00:00:0010-QStáhnout
2024-11-11 23:00:008-KStáhnout
2024-11-11 23:00:0010-QStáhnout
2024-09-11 01:00:008-KStáhnout
2024-09-11 00:00:008-KStáhnout
2024-08-13 01:00:008-KStáhnout
2024-08-13 01:00:0010-QStáhnout
2024-08-13 00:00:008-KStáhnout
2024-08-13 00:00:0010-QStáhnout
2024-08-02 01:00:008-KStáhnout
2024-08-02 00:00:008-KStáhnout
2024-07-01 01:00:008-KStáhnout
2024-07-01 00:00:008-KStáhnout
2024-06-28 01:00:008-KStáhnout
2024-06-28 00:00:008-KStáhnout
2024-06-17 01:00:008-KStáhnout
2024-06-17 00:00:008-KStáhnout
2024-06-07 01:00:008-KStáhnout
2024-06-07 00:00:008-KStáhnout
2024-05-14 01:00:008-KStáhnout
2024-05-14 01:00:0010-QStáhnout
2024-05-14 00:00:008-KStáhnout
2024-05-14 00:00:0010-QStáhnout
2024-03-08 00:00:008-KStáhnout
2024-03-08 00:00:0010-KStáhnout
2024-03-07 23:00:008-KStáhnout
2024-03-07 23:00:0010-KStáhnout
2023-12-06 00:00:008-KStáhnout
2023-12-05 23:00:008-KStáhnout
2023-11-03 00:00:008-KStáhnout
2023-11-03 00:00:0010-QStáhnout
2023-11-02 23:00:008-KStáhnout
2023-11-02 23:00:0010-QStáhnout
2023-10-18 01:00:008-KStáhnout
2023-10-18 00:00:008-KStáhnout
2023-10-02 01:00:008-KStáhnout
2023-10-02 00:00:008-KStáhnout
2023-08-04 01:00:008-KStáhnout
2023-08-04 01:00:0010-QStáhnout
2023-08-04 00:00:008-KStáhnout
2023-08-04 00:00:0010-QStáhnout
2023-06-09 01:00:008-KStáhnout
2023-06-09 00:00:008-KStáhnout
2023-05-05 01:00:008-KStáhnout
2023-05-05 01:00:0010-QStáhnout
2023-05-05 00:00:008-KStáhnout
2023-05-05 00:00:0010-QStáhnout
2023-05-01 01:00:008-KStáhnout
2023-05-01 00:00:008-KStáhnout
2023-04-27 01:00:008-KStáhnout
2023-04-27 00:00:008-KStáhnout
2023-03-13 00:00:008-KStáhnout
2023-03-13 00:00:0010-KStáhnout
2023-03-12 23:00:008-KStáhnout
2023-03-12 23:00:0010-KStáhnout
2023-03-10 00:00:008-KStáhnout
2023-03-09 23:00:008-KStáhnout
2022-11-08 00:00:008-KStáhnout
2022-11-08 00:00:0010-QStáhnout
2022-11-07 23:00:008-KStáhnout
2022-11-07 23:00:0010-QStáhnout
2022-08-09 01:00:008-KStáhnout
2022-08-09 01:00:0010-QStáhnout
2022-08-09 00:00:008-KStáhnout
2022-08-09 00:00:0010-QStáhnout
2022-06-10 01:00:008-KStáhnout
2022-06-10 00:00:008-KStáhnout
2022-05-11 01:00:008-KStáhnout
2022-05-11 00:00:008-KStáhnout
2022-05-10 01:00:008-KStáhnout
2022-05-10 01:00:0010-QStáhnout
2022-05-10 00:00:008-KStáhnout
2022-05-10 00:00:0010-QStáhnout
2022-03-15 00:00:008-KStáhnout
2022-03-15 00:00:0010-KStáhnout
2022-03-14 23:00:008-KStáhnout
2022-03-14 23:00:0010-KStáhnout
2022-01-03 00:00:008-KStáhnout
2022-01-02 23:00:008-KStáhnout
2021-11-10 00:00:008-KStáhnout
2021-11-10 00:00:0010-QStáhnout
2021-11-09 23:00:008-KStáhnout
2021-11-09 23:00:0010-QStáhnout
2021-10-07 01:00:008-KStáhnout
2021-10-07 00:00:008-KStáhnout
2021-08-18 01:00:008-KStáhnout
2021-08-18 00:00:008-KStáhnout
2021-08-16 01:00:008-KStáhnout
2021-08-16 01:00:0010-QStáhnout
2021-08-16 00:00:008-KStáhnout
2021-08-16 00:00:0010-QStáhnout
2021-07-08 01:00:008-KStáhnout
2021-07-08 00:00:008-KStáhnout
2021-06-23 01:00:008-KStáhnout
2021-06-23 00:00:008-KStáhnout
2021-06-11 01:00:008-KStáhnout
2021-06-11 00:00:008-KStáhnout
2021-06-04 01:00:008-KStáhnout
2021-06-04 00:00:008-KStáhnout
2021-05-18 01:00:008-KStáhnout
2021-05-18 00:00:008-KStáhnout
2021-05-13 01:00:008-KStáhnout
2021-05-13 01:00:0010-QStáhnout
2021-05-13 00:00:008-KStáhnout
2021-05-13 00:00:0010-QStáhnout
2021-04-19 01:00:008-KStáhnout
2021-04-19 00:00:008-KStáhnout
2021-04-09 01:00:008-KStáhnout
2021-04-09 00:00:008-KStáhnout
2021-04-01 01:00:008-KStáhnout
2021-04-01 00:00:008-KStáhnout
2021-03-30 01:00:008-KStáhnout
2021-03-30 00:00:008-KStáhnout
2021-03-15 00:00:008-KStáhnout
2021-03-15 00:00:0010-KStáhnout
2021-03-14 23:00:008-KStáhnout
2021-03-14 23:00:0010-KStáhnout
2021-03-03 00:00:008-KStáhnout
2021-03-02 23:00:008-KStáhnout
2020-12-21 00:00:008-KStáhnout
2020-12-20 23:00:008-KStáhnout
2020-12-01 00:00:008-KStáhnout
2020-11-30 23:00:008-KStáhnout
2020-11-13 00:00:0010-QStáhnout
2020-11-12 23:00:0010-QStáhnout
2020-11-12 00:00:008-KStáhnout
2020-11-11 23:00:008-KStáhnout
2020-10-22 01:00:008-KStáhnout
2020-10-22 00:00:008-KStáhnout
2020-09-30 01:00:008-KStáhnout
2020-09-30 00:00:008-KStáhnout
2020-08-26 01:00:008-KStáhnout
2020-08-26 00:00:008-KStáhnout
2020-08-25 01:00:008-KStáhnout
2020-08-25 00:00:008-KStáhnout
2020-08-10 01:00:008-KStáhnout
2020-08-10 01:00:0010-QStáhnout
2020-08-10 00:00:008-KStáhnout
2020-08-10 00:00:0010-QStáhnout
2020-07-13 01:00:008-KStáhnout
2020-07-13 00:00:008-KStáhnout
2020-06-19 01:00:008-KStáhnout
2020-06-19 00:00:008-KStáhnout
2020-06-17 01:00:008-KStáhnout
2020-06-17 00:00:008-KStáhnout
2020-06-05 01:00:008-KStáhnout
2020-06-05 00:00:008-KStáhnout
2020-05-07 01:00:008-KStáhnout
2020-05-07 01:00:0010-QStáhnout
2020-05-07 00:00:008-KStáhnout
2020-05-07 00:00:0010-QStáhnout
2020-03-30 01:00:008-KStáhnout
2020-03-30 00:00:008-KStáhnout
2020-03-13 00:00:008-KStáhnout
2020-03-12 23:00:008-KStáhnout
2020-03-11 00:00:008-KStáhnout
2020-03-11 00:00:0010-KStáhnout
2020-03-10 23:00:008-KStáhnout
2020-03-10 23:00:0010-KStáhnout
2020-03-02 00:00:008-KStáhnout
2020-03-01 23:00:008-KStáhnout
2020-01-07 00:00:008-KStáhnout
2020-01-06 23:00:008-KStáhnout
2019-12-24 00:00:008-KStáhnout
2019-12-23 23:00:008-KStáhnout
2019-11-08 00:00:008-KStáhnout
2019-11-08 00:00:0010-QStáhnout
2019-11-07 23:00:008-KStáhnout
2019-11-07 23:00:0010-QStáhnout
2019-11-01 00:00:008-KStáhnout
2019-10-31 23:00:008-KStáhnout
2019-10-08 01:00:008-KStáhnout
2019-10-08 00:00:008-KStáhnout
2019-09-24 01:00:008-KStáhnout
2019-09-24 00:00:008-KStáhnout
2019-09-23 01:00:008-KStáhnout
2019-09-23 00:00:008-KStáhnout
2019-09-19 01:00:008-KStáhnout
2019-09-19 00:00:008-KStáhnout
2019-09-12 01:00:008-KStáhnout
2019-09-12 00:00:008-KStáhnout
2019-09-09 01:00:008-KStáhnout
2019-09-09 00:00:008-KStáhnout
2019-08-07 01:00:008-KStáhnout
2019-08-07 01:00:0010-QStáhnout
2019-08-07 00:00:008-KStáhnout
2019-08-07 00:00:0010-QStáhnout
2019-07-02 01:00:008-KStáhnout
2019-07-02 00:00:008-KStáhnout
2019-06-27 01:00:008-KStáhnout
2019-06-27 00:00:008-KStáhnout
2019-06-18 01:00:008-KStáhnout
2019-06-18 00:00:008-KStáhnout
2019-06-10 01:00:008-KStáhnout
2019-06-10 00:00:008-KStáhnout
2019-05-15 01:00:008-KStáhnout
2019-05-15 00:00:008-KStáhnout
2019-05-07 01:00:008-KStáhnout
2019-05-07 01:00:0010-QStáhnout
2019-05-07 00:00:008-KStáhnout
2019-05-07 00:00:0010-QStáhnout
2019-03-28 00:00:008-KStáhnout
2019-03-27 23:00:008-KStáhnout
2019-03-21 00:00:008-KStáhnout
2019-03-20 23:00:008-KStáhnout
2019-03-11 00:00:008-KStáhnout
2019-03-10 23:00:008-KStáhnout
2019-03-07 00:00:008-KStáhnout
2019-03-07 00:00:0010-KStáhnout
2019-03-06 23:00:008-KStáhnout
2019-03-06 23:00:0010-KStáhnout
2019-03-01 00:00:008-KStáhnout
2019-02-28 23:00:008-KStáhnout
2019-02-21 00:00:008-KStáhnout
2019-02-20 23:00:008-KStáhnout
2019-02-19 00:00:008-KStáhnout
2019-02-18 23:00:008-KStáhnout
2019-01-07 00:00:008-KStáhnout
2019-01-06 23:00:008-KStáhnout
2019-01-04 00:00:008-KStáhnout
2019-01-03 23:00:008-KStáhnout
2018-12-17 00:00:008-KStáhnout
2018-12-16 23:00:008-KStáhnout
2018-12-06 00:00:008-KStáhnout
2018-12-05 23:00:008-KStáhnout
2018-11-08 00:00:008-KStáhnout
2018-11-08 00:00:0010-QStáhnout
2018-11-07 23:00:008-KStáhnout
2018-11-07 23:00:0010-QStáhnout
2018-10-25 01:00:008-KStáhnout
2018-10-25 00:00:008-KStáhnout
2018-10-01 01:00:008-KStáhnout
2018-10-01 00:00:008-KStáhnout
2018-09-04 01:00:008-KStáhnout
2018-09-04 00:00:008-KStáhnout
2018-08-09 01:00:008-KStáhnout
2018-08-09 01:00:0010-QStáhnout
2018-08-09 00:00:008-KStáhnout
2018-08-09 00:00:0010-QStáhnout
2018-08-06 01:00:008-KStáhnout
2018-08-06 00:00:008-KStáhnout
2018-07-19 01:00:008-KStáhnout
2018-07-19 00:00:008-KStáhnout
2018-07-16 01:00:008-KStáhnout
2018-07-16 00:00:008-KStáhnout
2018-06-11 01:00:008-KStáhnout
2018-06-11 00:00:008-KStáhnout
2018-05-08 01:00:008-KStáhnout
2018-05-08 01:00:0010-QStáhnout
2018-05-08 00:00:008-KStáhnout
2018-05-08 00:00:0010-QStáhnout
2018-03-29 01:00:008-KStáhnout
2018-03-29 01:00:0010-KStáhnout
2018-03-29 00:00:008-KStáhnout
2018-03-29 00:00:0010-KStáhnout
2018-01-24 00:00:008-KStáhnout
2018-01-23 23:00:008-KStáhnout
2017-12-11 00:00:008-KStáhnout
2017-12-10 23:00:008-KStáhnout
2017-12-04 00:00:008-KStáhnout
2017-12-03 23:00:008-KStáhnout
2017-11-09 00:00:008-KStáhnout
2017-11-09 00:00:0010-QStáhnout
2017-11-08 23:00:008-KStáhnout
2017-11-08 23:00:0010-QStáhnout
2017-10-16 01:00:008-KStáhnout
2017-10-16 00:00:008-KStáhnout
2017-10-10 01:00:008-KStáhnout
2017-10-10 00:00:008-KStáhnout
2017-08-15 01:00:008-KStáhnout
2017-08-15 00:00:008-KStáhnout
2017-08-10 01:00:008-KStáhnout
2017-08-10 01:00:0010-QStáhnout
2017-08-10 00:00:008-KStáhnout
2017-08-10 00:00:0010-QStáhnout
2017-06-22 01:00:008-KStáhnout
2017-06-22 00:00:008-KStáhnout
2017-06-15 01:00:008-KStáhnout
2017-06-15 00:00:008-KStáhnout
2017-06-14 01:00:008-KStáhnout
2017-06-14 00:00:008-KStáhnout
2017-06-13 01:00:0010-QStáhnout
2017-06-13 00:00:0010-QStáhnout
2017-06-09 01:00:008-KStáhnout
2017-06-09 00:00:008-KStáhnout
2017-05-10 01:00:008-KStáhnout
2017-05-10 00:00:008-KStáhnout
preloader